Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $2 | $2 | $2 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $1 | $0 |
| Other Curr. Assets | $1 | $1 | $1 | $0 |
| Total Curr. Assets | $3 | $3 | $3 | $0 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $26 | $26 | $24 | $0 |
| Intangibles | $148 | $156 | $146 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $2 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $174 | $183 | $171 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $177 | $185 | $175 | $2 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $15 | $15 | $14 | $5 |
| Total Curr. Liab. | $15 | $16 | $14 | $7 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $28 | $30 | $28 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $2 |
| Total NC Liab. | $28 | $30 | $28 | $2 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $43 | $46 | $42 | $9 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $2 |
| Retained Earnings | -$32 | -$30 | -$31 | -$8 |
| AOCI | $5 | $7 | $0 | $0 |
| Other Equity | $162 | $162 | $163 | $0 |
| Total Equity | $134 | $139 | $132 | -$6 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $52 | $55 | $57 | $0 |
| Total Liab. & Tot. Equity | $177 | $185 | $175 | $2 |
| Net Debt | -$2 | -$2 | -$1 | $2 |